Pentoxifylline effects on the treatment of non alcoholic steatohepatitis

Assessment of pentoxifillin effects on the serum level of inflammatory cytokines(IL-6, IL-8, TNF-a) and liver transaminases in patient with non alcoholic steatohepatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015033021565N1

Enrollment

Registered

2015-05-19

Start date

2013-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcoholic steatohepatitis. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: People in intervention group will treat with pentoxifylline for six months at a rate of one tablet of 400 mg three times a day. exercise and diet will advise for every one. Interventio

Treatment - Drugs

People in intervention group will treat with pentoxifylline for six months at a rate of one tablet of 400 mg three times a day. exercise and diet will advise for every one.

People in control group will treat with pelacebo for six months at a rate of one tablet three times a day. exercise and diet will advise for every one.

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of non alcoholic steatohepatitis is with clinical and paraclinical criteria (elevated ALT and AST to 1.5 times more than normal and sonography confirmation of fatty liver). Exclusion criteria: Diabetes mellitus; hyperlypidemia; liver diseases(Serum level, ASMA, ANA, FERRITIN, a-1anti tripsin, people with positive markers hepaptitis B virus, hepatitis c & hepatitis a); drug users (Calsium channel blocker, B blocker, amiodarone, glucocorticoids, strogen,...); alcoholic users; people who intervened before and during acute or chronic liveror systemic disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ALT. Timepoint: Before the intervention, third month after intervention, sixth mounth after intervention. Method of measurement: Blood Exam.;AST. Timepoint: Before the intervention, third month after intervention, sixth mounth after intervention. Method of measurement: Blood Exam.;BMI. Timepoint: Before the intervention, third month after intervention, sixth mounth after intervention. Method of measurement: height measurement with tape and weight measurement with digital scale.;IL-6. Timepoint: Before the intervention, sixth mounth after intervention. Method of measurement: Elisa Exam.;IL-8. Timepoint: Before the intervention, sixth mounth after intervention. Method of measurement: Elisa Exam.;TNF-a. Timepoint: bBfore the intervention, sixth mounth after intervention. Method of measurement: Elisa Exam.	—

Measure

Time frame

ALT. Timepoint: Before the intervention, third month after intervention, sixth mounth after intervention. Method of measurement: Blood Exam.;AST. Timepoint: Before the intervention, third month after intervention, sixth mounth after intervention. Method of measurement: Blood Exam.;BMI. Timepoint: Before the intervention, third month after intervention, sixth mounth after intervention. Method of measurement: height measurement with tape and weight measurement with digital scale.;IL-6. Timepoint: Before the intervention, sixth mounth after intervention. Method of measurement: Elisa Exam.;IL-8. Timepoint: Before the intervention, sixth mounth after intervention. Method of measurement: Elisa Exam.;TNF-a. Timepoint: bBfore the intervention, sixth mounth after intervention. Method of measurement: Elisa Exam.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Nadieh Baniasadi

Kerman Univercity of Medical Sciences

baniasadi.n@gmail.com+34 33222250

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026